Compare USLM & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USLM | AKRO |
|---|---|---|
| Founded | 1948 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 4.5B |
| IPO Year | N/A | 2019 |
| Metric | USLM | AKRO |
|---|---|---|
| Price | $121.24 | $54.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $73.56 |
| AVG Volume (30 Days) | 57.0K | ★ 1.7M |
| Earning Date | 10-29-2025 | 11-07-2025 |
| Dividend Yield | ★ 0.20% | N/A |
| EPS Growth | ★ 32.23 | N/A |
| EPS | ★ 4.55 | N/A |
| Revenue | ★ $364,849,000.00 | N/A |
| Revenue This Year | $22.64 | N/A |
| Revenue Next Year | $8.38 | N/A |
| P/E Ratio | $26.69 | ★ N/A |
| Revenue Growth | ★ 20.27 | N/A |
| 52 Week Low | $80.47 | $21.34 |
| 52 Week High | $154.79 | $58.40 |
| Indicator | USLM | AKRO |
|---|---|---|
| Relative Strength Index (RSI) | 52.60 | 66.54 |
| Support Level | $116.76 | $54.22 |
| Resistance Level | $122.10 | $54.70 |
| Average True Range (ATR) | 3.33 | 0.14 |
| MACD | 0.50 | -0.11 |
| Stochastic Oscillator | 65.33 | 64.18 |
United States Lime & Minerals Inc is engaged in the business of manufacturing lime and limestone products including PLS, quicklime, hydrated lime and lime slurry. It supplies its products predominantly to the construction (including highway, road, and building contractors), industrial (including paper and glass manufacturers), environmental (including municipal sanitation and water treatment facilities and flue gas treatment processes), metals (including steel producers), oil and gas services, roof shingle manufacturers and agriculture (including poultry and cattle feed producers) industries. The company operates through its Lime and Limestone Operations segment.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.